161 related articles for article (PubMed ID: 26103538)
21. An evaluation of early cardiometabolic risk factors in children and adolescents with Turner syndrome.
O'Gorman CS; Syme C; Lang J; Bradley TJ; Wells GD; Hamilton JK
Clin Endocrinol (Oxf); 2013 Jun; 78(6):907-13. PubMed ID: 23106295
[TBL] [Abstract][Full Text] [Related]
22. Complement C3 as a marker of cardiometabolic risk in psoriasis.
Torres T; Bettencourt N; Mendonça D; Vasconcelos C; Silva BM; Selores M
Arch Dermatol Res; 2014 Sep; 306(7):653-60. PubMed ID: 24848273
[TBL] [Abstract][Full Text] [Related]
23. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients.
Lee SH; Park SA; Ko SH; Yim HW; Ahn YB; Yoon KH; Cha BY; Son HY; Kwon HS
Metabolism; 2010 Feb; 59(2):241-6. PubMed ID: 19765773
[TBL] [Abstract][Full Text] [Related]
24. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Cusi K
Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
[TBL] [Abstract][Full Text] [Related]
25. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH.
Anty R; Bekri S; Luciani N; Saint-Paul MC; Dahman M; Iannelli A; Amor IB; Staccini-Myx A; Huet PM; Gugenheim J; Sadoul JL; Le Marchand-Brustel Y; Tran A; Gual P
Am J Gastroenterol; 2006 Aug; 101(8):1824-33. PubMed ID: 16790033
[TBL] [Abstract][Full Text] [Related]
26. Coinhibitory suppression of T cell activation by CD40 protects against obesity and adipose tissue inflammation in mice.
Wolf D; Jehle F; Michel NA; Bukosza EN; Rivera J; Chen YC; Hoppe N; Dufner B; Rodriguez AO; Colberg C; Nieto L; Rupprecht B; Wiedemann A; Schulte L; Peikert A; Bassler N; Lozhkin A; Hergeth SP; Stachon P; Hilgendorf I; Willecke F; von Zur Mühlen C; von Elverfeldt D; Binder CJ; Aichele P; Varo N; Febbraio MA; Libby P; Bode C; Peter K; Zirlik A
Circulation; 2014 Jun; 129(23):2414-25. PubMed ID: 24664276
[TBL] [Abstract][Full Text] [Related]
27. Toll-like receptors, inflammation, metabolism and obesity.
Fresno M; Alvarez R; Cuesta N
Arch Physiol Biochem; 2011 Jul; 117(3):151-64. PubMed ID: 21599616
[TBL] [Abstract][Full Text] [Related]
28. Psoriasis as the marker of underlying systemic disease.
Kourosh AS; Miner A; Menter A
Skin Therapy Lett; 2008 Feb; 13(1):1-5. PubMed ID: 18357363
[TBL] [Abstract][Full Text] [Related]
29. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation.
Wensveen FM; Valentić S; Šestan M; Turk Wensveen T; Polić B
Eur J Immunol; 2015 Sep; 45(9):2446-56. PubMed ID: 26220361
[TBL] [Abstract][Full Text] [Related]
30. The cardiometabolic syndrome in the adolescent.
Gardner M; Gardner DW; Sowers JR
Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():964-8. PubMed ID: 18806711
[TBL] [Abstract][Full Text] [Related]
31. Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers.
Lima MM; Pareja JC; Alegre SM; Geloneze SR; Kahn SE; Astiarraga BD; Chaim ÉA; Baracat J; Geloneze B
Obesity (Silver Spring); 2013 Mar; 21(3):E182-9. PubMed ID: 23404948
[TBL] [Abstract][Full Text] [Related]
32. [Markers of endocrine system and inflammation as prognostic risk factors of vascular complications of type 2 diabetes mellitus].
Verbovoĭ AF; Morkovskikh NV
Vestn Ross Akad Med Nauk; 2011; (3):37-42. PubMed ID: 21542374
[TBL] [Abstract][Full Text] [Related]
33. Immunity as a link between obesity and insulin resistance.
Kalupahana NS; Moustaid-Moussa N; Claycombe KJ
Mol Aspects Med; 2012 Feb; 33(1):26-34. PubMed ID: 22040698
[TBL] [Abstract][Full Text] [Related]
34. [Metabolic or immunometabolic syndrome?].
Wysocki J; Skoczyński S; Strózik A; Hochuł B; Zyguła M
Wiad Lek; 2005; 58(1-2):124-7. PubMed ID: 15991565
[TBL] [Abstract][Full Text] [Related]
35. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
Gisondi P; Girolomoni G
Semin Thromb Hemost; 2009 Apr; 35(3):313-24. PubMed ID: 19452407
[TBL] [Abstract][Full Text] [Related]
36. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
Després JP; Lemieux I; Bergeron J; Pibarot P; Mathieu P; Larose E; Rodés-Cabau J; Bertrand OF; Poirier P
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1039-49. PubMed ID: 18356555
[TBL] [Abstract][Full Text] [Related]
37. Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk.
Billups KL; Miner MM; Wierzbicki AS; Jackson G
Int J Clin Pract; 2011 Feb; 65(2):134-47. PubMed ID: 21199197
[TBL] [Abstract][Full Text] [Related]
38. Inflammation, the metabolic syndrome and cardiovascular risk.
Tracy RP
Int J Clin Pract Suppl; 2003 Mar; (134):10-7. PubMed ID: 12793593
[TBL] [Abstract][Full Text] [Related]
39. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes.
Diamant M; Lamb HJ; van de Ree MA; Endert EL; Groeneveld Y; Bots ML; Kostense PJ; Radder JK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1495-501. PubMed ID: 15613416
[TBL] [Abstract][Full Text] [Related]
40. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease.
Tan BK; Adya R; Randeva HS
Trends Cardiovasc Med; 2010 Jul; 20(5):143-8. PubMed ID: 21742269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
